Skip to main content
SpringerLink
Log in

Future Directions to Establish Lipoprotein(a) as a Treatment for Atherosclerotic Cardiovascular Disease

  • REVIEW ARTICLE
  • Published:
Cardiovascular Drugs and Therapy Aims and scope Submit manuscript

Abstract

In both epidemiologic and genetic studies, increased levels of Lp(a) have been associated with increased risk for cardiovascular diseases as well as aortic stenosis. However, until recently, it has been difficult to lower levels of Lp(a). Diet and lifestyle have little effect on plasma levels of Lp(a) which are mainly genetically determined. Emerging therapeutic agents which have recently become available, or which are undergoing clinical trials, can significantly lower Lp(a) levels. Studies with these agents will hopefully be able to provide more direct information whether reductions in Lp(a) will reduce CVD events independently of reduction in LDL-cholesterol levels.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Boerwinkle E, Leffert C, Lin J, Lackner C, Chiesa G, Hobbs HH. Apolipoprotein (a) gene accounts for greater than 90 % of the variation in plasma lipoprotein (a) concentrations. J Clin Invest. 1992;90:52–60.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Rader DJ, Cain W, Ikewaki K, et al. The inverse association of plasma lipoprotein(a) concentrations with apolipoprotein(a) isoform size is not due to differences in Lp(a) catabolism but to differences in production rate. J Clin Invest. 1994;93:2758–63.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Virani SS, Brautbar A, Davis BC, et al. Associations between lipoprotein(a) levels and cardiovascular outcomes in black and white subjects: the Atherosclerosis Risk in Communities (ARIC) study. Circulation. 2012;125:241–49.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Heinrich J, Sandkamp M, Kokott R. Relationship of lipoprotein(a) to variables of coagulation and fibrinolysis in a healthy population. Clin Chem. 1991;37:1950–4.

    CAS  PubMed  Google Scholar 

  5. Hoover-Plow J, Haung M. Lipoprotein(a) metabolism: potential sites for therapeutic targets. Metabolism. 2013;62:479–91.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Howard BV, Roussouw JE. Estrogens and cardiovascular disease risk revisited: the Women’s Health Initiative. Curr Opin Lipidol. 2013;24:493–99.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Schlant RC, Forman S, Stamler J, Canner PL. The natural history of coronary heart disease: prognostic factors after recovery from myocardial infarction in 2789 men. the 5-year findings of the coronary drug project. Circulation. 1982;66(2):401–14.

    Article  CAS  PubMed  Google Scholar 

  8. Ledue TB, Neveux LM, Palomaki GE, Ritchie RF, Craig WY. The relationship between serum levels of lipoprotein (a) and proteins associated with acute phase response. Clin Chim Acta. 1993;223:73–82.

    Article  CAS  PubMed  Google Scholar 

  9. Maeda S, Abe A, Seishima M, Makino K, Noma A, Kawade M. Transient changes of serum lipoprotein(a) as an acute phase protein. Atherosclerosis. 1989;78:145–50.

    Article  CAS  PubMed  Google Scholar 

  10. Mbewu AD, Durrington PN, Bulleid S, et al. The immediate effect of streptokinase on serum lipoprotein (a) concentration and the effect of myocardial infarction on serum lipoprotein (a), apolipoprotein A1 and B, lipids and C-reactive protein. Atherosclerosis. 1993;103:65–71.

    Article  CAS  PubMed  Google Scholar 

  11. Gidding SS, Stone NJ, Bookstein LC, Laskarzewski PM, Stein EA. Month-to-month variability of lipids, lipoproteins, and apolipoproteins and the impact of acute infection in adolescents. J Pediatr. 1998;133:242–6.

    Article  CAS  PubMed  Google Scholar 

  12. Mooser V, Berger MM, Tappy L, Cayeux C, Markovina SM, Darioli R, et al. Major reduction in plasma Lp(a) levels during sepsis and burns. Arterioscler Thromb Vasc Biol. 2000;20:1137–42.

    Article  CAS  PubMed  Google Scholar 

  13. Noma A, Abe A, Maeda S. Lp(a): an acute-phase reactant? Chem Phys Lipids. 1994;67/68:411–17.

    Article  Google Scholar 

  14. De Bruin T, van Barlingen H, van Linde-Sibenius TM, et al. Lipoprotein(a) and apolipoprotein B plasma concentrations in hypothyroid, euthyroid and hyperthyroid subjects. J Clin Endocrinol Metab. 1993;76:121–26.

    PubMed  Google Scholar 

  15. Landerson PW, Kristensen JD, Ridgeway EC, et al. Use of the thyroid hormone analogue eprotirome in statin treated dyslipidemia. N Engl J Med. 2010;362:906–16.

    Article  Google Scholar 

  16. Sjouke B, Langslet G, Ceska R, et al. Eprotirome in patients with familial hypercholesterolaemia (the AKKA trial): a randomised, double-blind, placebo controlled phase 3 study. Lancet Diabetes Endocrinol. 2014;2:455–63.

    Article  CAS  PubMed  Google Scholar 

  17. Krempler F, Kostner GM, Roscher A, et al. Studies on the role of specific cell surface receptors in the removal of lipoprotein(a) in man. J Clin Invest. 1983;71:1431–41.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Hofer G, Steyrer E, Kostner GM, Hermetter A. LDL-mediated interaction of Lp(a) with HepG2 cells: a novel fluorescence microscopy approach. J Lipid Res. 1997;38:2411–21.

    CAS  PubMed  Google Scholar 

  19. Hafner S, Orchard T, Stein E, Schmidt D, LaBelle P. Effect of simvastatin on Lp(a) concentrations. Clin Cardiol. 1995;18:261–5.

    Article  Google Scholar 

  20. Illingworth DR, Stein EA, Mitchel YB, Dujovne CA, Frost PH, Knopp RH, et al. Comparative effects of lovastatin and niacin in primary hypercholesterolemia: a prospective trial. Arch Intern Med. 1994;154:1586–95.

    Article  CAS  PubMed  Google Scholar 

  21. Hunninghake DB, Stein EA, Mellies MJ. Effects of one year of treatment with pravastatin, an HMG-CoA reductase inhibitor, on lipoprotein a. J Clin Pharmacol. 1993;33(6):574–80.

    Article  CAS  PubMed  Google Scholar 

  22. Fieseler HG, Armstrong VW, Wieland E, Thiery J, Schutz E, Walli AK, et al. Serum Lp(a) concentrations are unaffected by treatment with the HMG-CoA reductase inhibitor Pravastatin: results of a 2-year investigation. Clin Chim Acta. 1991;204(1–3):291–300.

    Article  CAS  PubMed  Google Scholar 

  23. Gonbert S, Malinsky S, Sposito AC, Laouenan H, Doucet C, Chapman MJ, et al. Atorvastatin lowers lipoprotein(a) but not apolipoprotein(a) fragment levels in hypercholesterolemic subjects at high cardiovascular risk. Atherosclerosis. 2002;164:305–11.

    Article  CAS  PubMed  Google Scholar 

  24. van Wissen S, Smilde TJ, Trip MD, de Boo T, Kastelein JJP, Stalenhoef AFH. Long term statin treatment reduces lipoprotein(a) concentrations in heterozygous familial hypercholesterolaemia. Heart. 2003;89:893–6.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Khera AV, Everett BM, Caulfield MP, Hantash FM, Wohlgemuth J, Ridker PM, et al. Lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER Trial (Justification for the use of statins in prevention: an Intervention Trial Evaluating Rosuvastatin). Circulation. 2014;129:635–42.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Berg K, Dahlen G, Christopherson B, et al. Lp(a) lipoprotein level predicts survival and major coronary events in the Scandinavian Simvastatin Survival Study. Clin Genet. 1997;52:254–61.

    Article  CAS  PubMed  Google Scholar 

  27. Sudhop T, Lutjohann D, Kodal A, et al. Inhibition of intestinal cholesterol absorption by ezetimibe in humans. Circulation. 2002;106:1943–8.

    Article  CAS  PubMed  Google Scholar 

  28. Knopp RH, Gitter H, Truitt T. Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia. Eur Heart J. 2003;23:729–41.

    Article  Google Scholar 

  29. Nozue T, Michishati I, Mizuguchi I. Effects of ezetimibe on remnant-like particle cholesterol, lipoprotein(a) and oxidized low-density lipoprotein in patients with dyslipidaemia. J Atheroscler Thromb. 2010;17(1):37–44.

    Article  CAS  PubMed  Google Scholar 

  30. Gagne C, Gaudet D, Bruckert E, et al. Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia. Circulation. 2002;105:2469–75.

    Article  CAS  PubMed  Google Scholar 

  31. Moutzouri E, Liberopoulos E, Mikhailidis DP, et al. Comparison of the effects of simvastatin vs. rosuvastatin vs. simvastatin/ezetimibe on parameters of insulin resistance. Int J Clin Pract. 2011;65:1141–8.

    Article  CAS  PubMed  Google Scholar 

  32. Chennamsetty I, Claudel T, Kostner KM, et al. Farsenoid X receptor represses hepatic human apo(a) gene expression. J Clin Invest. 2011;121:3724–34.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Gurakar K, Hoeg JM, Kostner G, Papadopolous NM. Brewer HBJr, levels of lipoprotein (a) Lp(a) decline with neomycin and niacin treatment. Atherosclerosis. 1985;57:293–301.

    Article  CAS  PubMed  Google Scholar 

  34. Carlson LA, Hamsten A, Asplund A. Pronounced lowering of levels of lipoprotein (a) Lp(a) in hyperlipidemic subjects treated with nicotinic acid. J Intern Med. 1989;226:271–6.

    Article  CAS  PubMed  Google Scholar 

  35. Stein EA, Davidson MH, Dujovne CA, Hunninghake DB, et al. Efficacy and tolerability of low dose simvastatin and niacin, alone and in combination, in patients with combined hyperlipidemia: a prospective trial. J Cardiovasc Pharmacol Ther. 1996;1:107–16.

    CAS  PubMed  Google Scholar 

  36. Grundy SM, Vega GL, McGovern ME, Tulloch BR, Kendall DM, Fitz-Patrick D, et al. Sheehan JP; Diabetes Multicenter Research Group. Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial. Arch Intern Med. 2002;162(14):1568–76.

    Article  CAS  PubMed  Google Scholar 

  37. Capuzzi DM, Guyton JR, Morgan JM, Goldberg AC, Kreisberg RA, Brusco OA. Brody. Efficacy and safety of an extended-release niacin (Niaspan): a long-term study. Am J Cardiol. 1998;82(12A):74U–81U.

    Article  CAS  PubMed  Google Scholar 

  38. Goldberg AC. Clinical trial experience with extended-release niacin (Niaspan): dose-escalation study. Am J Cardiol. 1998;82(12A):35U–8U.

    Article  CAS  PubMed  Google Scholar 

  39. Sposito AC, Mansur AP, Maranhão RC, Rodrigues-Sobrinho CRM, Coelho OR, Ramires JAF. Etofibrate but not controlled-release niacin decreases LDL cholesterol and lipoprotein (a) in type IIb dyslipidemic subjects. Braz J Med Biol Res. 2001;34:177–82.

    Article  CAS  PubMed  Google Scholar 

  40. Shearer GC, Pottala JV, Hansen SN, Brandenburg V, Harris WS. Effects of prescription niacin and omega-3 fatty acids on lipids and vascular function in metabolic syndrome: a randomized controlled trial[S]. J Lipid Res. 2012;53:2429–35.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Visser ME, Witztum JL, Stroes ES, Kastelein JJ. Antisense oligonucleotides for the treatment of dyslipidaemia. Eur Heart J. 2012;33:1451–58.

    Article  CAS  PubMed  Google Scholar 

  42. Santos RD, Raal FJ, Catapano A, et al. Mipomersen, an antisense oligonucleotide to apolipoprotein B-100, reduces lipoprotein(a) in various populations with hypercholesterolemia: results of 4 phase III trials. Arterioscler Thromb Vasc Biol. 2015;35:689–99.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Santos RD, Duell PB, East C, et al. Long-term efficacy and safety of mipomersen in patients with familial hypercholesterolemia: 2-year interim results of an open-label extension. Eur Heart J. 2015;36:566–75.

    Article  PubMed  PubMed Central  Google Scholar 

  44. Raal FJ, Santos RD, Blom DJ, et al. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of lower LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet. 2010;375:998–1006.

    Article  CAS  PubMed  Google Scholar 

  45. Samaha FF, McKenney J, Bloedon LT, Sasiela WJ, Rader DJ. Inhibition of microsomal triglyceride transfer protein alone or with ezetimibe in patients with moderate hypercholesterolemia. Nat Clin Pract Cardiovasc Med. 2008;5:497–505.

    Article  CAS  PubMed  Google Scholar 

  46. Cuchel M, Meagher EA, du Toit TH, Blom DJ, Marais AD, Hegele RA, et al. Phase 3 HoFH Lomitapide Study Investigators. efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study. Lancet. 2013;381:40–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Thompson GR, Barbir M, Davies D, Dobral P, Gesinde M, Livingston M, et al. Efficacy criteria and cholesterol targets for LDL apheresis. Atherosclerosis. 2010;208:317–21.

    Article  CAS  PubMed  Google Scholar 

  48. Gordon BR, Kelsey SF, Bilheimer DW, Brown DC, Dau PC, Gotto AM, et al. For the Liposorber Study Group, treatment of refractory familial hypercholesterolemia by low-density lipoprotein apheresis using an automated dextran sulfate cellulose absorption system. Am J Cardiol. 1992;70:1010–6.

    Article  CAS  PubMed  Google Scholar 

  49. Leebmann J, Roeseler E, Julius U, Heigl F, et al. Lipoprotein apheresis in patients with maximally tolerated lipid-lowering therapy, lipoprotein(a)-hyperlipoproteinemia, and progressive cardiovascular disease: prospective observational multicenter study. Circulation. 2013;128:2567–76.

    Article  CAS  PubMed  Google Scholar 

  50. Cannon CP, Shah S, Dansky HM, Davidson M, Brinton EA, Gotto AM, et al. For the DEFINE Investigators Safety of anacetrapib in patients with, or at high risk for coronary heart disease. N Engl J Med. 2010;363:2406–15.

    Article  CAS  PubMed  Google Scholar 

  51. Hovingh GK, Kastelein JJP, van Deventer SJH, Round P, Ford J, Saleheen D, et al. Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipidaemia (TULIP): a randomised, double-blind, placebo-controlled phase 2 trial. Lancet. 2015.

  52. Nicholls SJ, Ruotolo G, Brewer BH, Wang MD, Liu L, Willey MB, et al. Evacetrapib alone or in combination with statins lowers lipoprotein(a) and total and small LDL particle concentrations in mildly hypercholesterolemic patients. J Clin Lipidol. 2015. doi:10.1016/j.jacl.2015.11.014.

  53. HPS3/TIMI55 – REVEAL trial of Anacetrapib in high-risk vascular patients recruits the target of 30,000 participantshttps://www.ctsu.ox.ac.uk/research/mega-trials/hps3-reveal [accessed January 10, 2016].

  54. Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, Komajda M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007;357:2109–22.

    Article  CAS  PubMed  Google Scholar 

  55. Schwartz GG, Olsson AG, Abt M, et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med. 2012;367:2089–99.

    Article  CAS  PubMed  Google Scholar 

  56. Lilly to discontinue development of evacetrapib for high-risk atherosclerotic cardiovascular disease. https://investor.lilly.com/releasedetail.cfm?ReleaseID=936130 [accessed January 12, 2016].

  57. Stein EA, Mellis S, Yancopoulos GD, Stahl N, Logan D, Smith WB, et al. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. N Engl J Med. 2012;366:1108–18.

    Article  CAS  PubMed  Google Scholar 

  58. Raal FJ, Giugliano RP, Sabatine MS, Koren MJ, Langslet G, Bays H, et al. Reduction in lipoprotein (a) with the PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of over 1300 patients in 4 phase 2 trials. J Am Coll Cardiol. 2014;63(13):1278–88.

    Article  CAS  PubMed  Google Scholar 

  59. Robinson JG, Farnier M, Krempf M, et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372:1489–99.

    Article  CAS  PubMed  Google Scholar 

  60. Kastelein JJ, Robinson JG, Farnier M, Krempf M, Langslet G, Lorenzato C, et al. Efficacy and safety of alirocumab in patients with heterozygous familial hypercholesterolemia not adequately controlled with current lipid-lowering therapy: design and rationale of the ODYSSEY FH studies. Cardiovasc Drugs Ther. 2014;28(3):281–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  61. Farnier M, Jones P, Severance R, Averna M, Steinhagen-Thiessen E, Colhoun HM, et al. Donahue S Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular risk patients: The ODYSSEY OPTIONS II randomized trial. Atherosclerosis. 2016;244:138–46.

    Article  CAS  PubMed  Google Scholar 

  62. McKenney JM, Koren MJ, Kereiakes DJ, Hanotin C, Ferrand A-C, Stein EA. Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy. J Am Coll Cardiol. 2012;59:2344–53.

    Article  CAS  PubMed  Google Scholar 

  63. Sabatine MS, Giugliano RP, Wiviott SD, Raal FJ, Blom DJ, Robinson J, et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. New Engl J Med. 2015;372:1500–9.

    Article  CAS  PubMed  Google Scholar 

  64. Graham MJ, Viney N, Crooke R, Tsimikas S. Antisense inhibition of apolipoprotein(a) to lower plasma lipoprotein(a) levels in humans. J Lipid Res. 2015 Nov 4.

  65. Tsimikas S, Viney NJ, Hughes SG, et al. Antisense therapy 674 targeting apolipoprotein(a): a randomised, double-blind, placebo- 675 controlled phase 1 study. Lancet. 2015;386:1472–83.

Download references

Author information

Authors and Affiliations

  1. Metabolic and Atherosclerosis Research Center, Cincinnati, OH, USA

    Evan A. Stein

  2. Carbohydrate & Lipid Metabolism Research Unit, Faculty of Health Sciences, University of Witwatersrand, Johannesburg, South Africa

    Frederick Raal

Authors
  1. Evan A. Stein
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Frederick Raal
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Evan A. Stein.

Ethics declarations

Disclosures

Dr. Stein has received consulting fees from Amgen, Regeneron, Sanofi, Genentech/Roche, CymaBay, Gemphire, Catabasis, CVS/Caremark and BMS.

Dr. Raal has received reimbursement for conducting clinical trials from Amgen and Sanofi; modest speaker fees from AstraZeneca, Pfizer, and Merck; honoraria from AstraZeneca, Pfizer, Merck, Amgen, and Sanofi; and consultant/advisory board fees from AstraZeneca, Pfizer, and Merck.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Stein, E.A., Raal, F. Future Directions to Establish Lipoprotein(a) as a Treatment for Atherosclerotic Cardiovascular Disease. Cardiovasc Drugs Ther 30, 101–108 (2016). https://doi.org/10.1007/s10557-016-6654-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10557-016-6654-5

Keywords

Search

Navigation